Opticyte

Opticyte is pioneering a breakthrough in patient monitoring with its VitalO₂ device, which has received FDA Breakthrough Device Designation. The device aims to detect cellular oxygen deficiency (cytopathic hypoxia) in real-time, allowing for earlier intervention in life-threatening conditions such as sepsis, trauma, and respiratory failure. By combining cellular and blood oxygen measurements in a skin-tone unbiased system, Opticyte targets a critical gap in current standard-of-care diagnostics, particularly the well-documented inaccuracies of conventional pulse oximeters in patients with darker skin. The company is positioned to address a massive global healthcare need while advancing health equity.

Non-invasive, real-time monitoring platform combining cellular oxygen measurement (via cytochrome c oxidase) and skin-tone unbiased pulse oximetry, powered by machine learning trained on diverse skin-tone datasets.

Competition includes large, established patient monitoring companies (e.g., Masimo, Medtronic, Philips) that dominate pulse oximetry and are working to address skin-tone bias. Opticyte's primary differentiation is its unique cellular oxygen measurement, for which there are no direct commercial competitors currently.